Trump declares nationwide Medicaid drug pricing model

President Donald Trump revealed on Friday that a program designed to facilitate Most Favored Nation pricing for certain Medicaid drugs has now been embraced by all 50 states. The move aims to match the net cost of these drugs with the prices in selected foreign countries.

The Trump administration’s project, named the Medicaid “GENEROUS” model, is expected to result in significant savings on prescription medication expenditures for Medicaid, according to their claim. However, the actual savings remain uncertain as the specifics of these agreements are not available to the public.

Speaking from the Oval Office on Friday, Trump said, “This one thing alone should win us the midterms.” He was joined by Health and Human Services Secretary Robert F. Kennedy Jr., Mehmet Oz, the Administrator for Centers for Medicare & Medicaid Services, amongst others.

This announcement comes at a time when affordability and cost of living are primary concerns for voters, especially with the upcoming midterm elections in November. To address these concerns, Trump has brokered deals with pharmaceutical companies to ensure certain drug prices in the U.S. aren’t substantially higher than in other affluent countries. Nevertheless, critics argue that his administration lacks a comprehensive strategy for tackling soaring health costs, particularly after the expiration of Affordable Care Act subsidies earlier this year, which resulted in a spike in plan costs.

Trump had implemented a “Most Favored Nations” policy last year via an executive order, promising that the U.S. would match the lowest global price for medications.

In May, the White House estimated that the deals Trump has arranged with pharmaceutical companies to lower some prescription drug prices in the U.S. to levels seen in other countries could result in savings of $529 billion over ten years.

While Medicaid patients, who are part of the state and federally funded program for individuals with low income, currently pay only a small co-payment for their prescriptions, reduced prices could potentially ease state budgets that finance these programs.

Trump added, “Every state will have the ability to use those extra billions of dollars to invest in other healthcare improvements or something else.”

The actual cost of these claimed savings is not clear as the specifics of deals between the Trump administration and pharmaceutical companies remain undisclosed, making it difficult to independently verify the projected savings.

White House spokesman Kush Desai referred to drug deals negotiated during former President Joe Biden’s term under the Inflation Reduction Act which also did not disclose commercially sensitive information. He suggested that experts criticizing the Trump administration for similar reasons are “either an idiot or partisan hack.”

Kathy Hempstead, a senior policy advisor at the Robert Wood Johnson Foundation, expressed to The Associated Press that the administration is under considerable pressure to provide specific data to support its cost-saving claims. She stated that the lack of information creates an obstacle to legislative action.

“He is saying Congress should codify all of his MFN arrangements,” said Hempstead. “But it’s kind of unreasonable because it’s not clear what Congress would actually do. No one knows what is in these deals.”

Concerns have been raised regarding the potential impact of the current administration’s tenure on the longevity of these price cuts and if prices will revert once the administration changes.

There are calls for broader access to lower drug pricing. JD Hayworth, a former Republican congressman and spokesperson for the Pharmaceutical Reform Alliance, said the recent announcement signals “meaningful progress, but that progress remains incomplete,” as he advocated for lower drug prices for millions of Americans not enrolled in government healthcare.

Drug prices for U.S. patients can be influenced by various factors, including competition and insurance coverage. Most people are covered through their employment, individual insurance plans, or government programs like Medicaid and Medicare, providing them some protection against high costs.